1. Home
  2. CBAT vs LUNG Comparison

CBAT vs LUNG Comparison

Compare CBAT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CBAK Energy Technology Inc.

CBAT

CBAK Energy Technology Inc.

N/A

Current Price

$0.98

Market Cap

71.5M

Sector

Miscellaneous

ML Signal

N/A

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

N/A

Current Price

$1.83

Market Cap

72.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CBAT
LUNG
Founded
1999
1995
Country
China
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Industrial Specialties
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.5M
72.2M
IPO Year
2006
2020

Fundamental Metrics

Financial Performance
Metric
CBAT
LUNG
Price
$0.98
$1.83
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
249.9K
645.4K
Earning Date
01-01-0001
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
533.33
10.00
EPS
N/A
N/A
Revenue
$176,614,609.00
$83,789,000.00
Revenue This Year
$16.06
$6.20
Revenue Next Year
$70.59
$21.61
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.01
52 Week Low
$0.57
$1.31
52 Week High
$1.25
$8.10

Technical Indicators

Market Signals
Indicator
CBAT
LUNG
Relative Strength Index (RSI) 60.28 57.62
Support Level $0.83 $1.44
Resistance Level $1.06 $1.93
Average True Range (ATR) 0.06 0.16
MACD -0.00 0.06
Stochastic Oscillator 68.18 56.00

Price Performance

Historical Comparison
CBAT
LUNG

About CBAT CBAK Energy Technology Inc.

CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: